ALK+, CD30−, CD20− Large B-Cell Lymphoma Containing Anaplastic Lymphoma Kinase (ALK) Fused to Clathrin Heavy Chain Gene (CLTC)

Chikatsu, Norio; Kojima, Hiroshi; Suzukawa, Kazumi; Shinagawa, Atsushi; Nagasawa, Toshiro; Ozawa, Hiroaki; Yamashita, Yoshihisa; Mori, Naoyoshi

doi:10.1097/01.mp.0000081729.40230.1f

Cited by 76 publications

(72 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The resulting fusion protein, NPM-ALK has constitutive tyrosine kinase activity and has been shown to transform various hematopoietic cell types in vitro and support tumor formation in vivo (1,6). Other less frequent ALK fusion partners, e.g., tropomyosin-3 and clathrin heavy chain, have also been identified in ALCL as well as in CD30-negative diffuse large-cell lymphoma (1,2,7,8). Despite subtle differences in signaling and some biological functions, all fusions appear to be transforming to fibroblasts and hematopoietic cells (9).…”

mentioning

confidence: 99%

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK

Galkin

Melnick

Kim

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

336

333

View full text Add to dashboard Cite

Constitutive overexpression and activation of NPM-ALK fusion protein [t(2:5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large-cell lymphomas (ALCLs). We have identified a highly potent and selective small-molecule ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC 50 values between 2 and 10 nM. NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest. In vivo , NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-positive ALCL and induced regression of established Karpas-299 lymphomas. NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition.

show abstract

mentioning

confidence: 99%

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK

Galkin

Melnick

Kim

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

336

333

View full text Add to dashboard Cite

show abstract

“…Of note, a recent description of this same translocation in an ALK ϩ DLBCL Japanese patient has appeared in abstract form. 27 Thus, 2 of 3 cases with a clonal karyotype thus far reported have a t(2;17) or variant. 7,27 These findings, together with the characteristic restricted granular cytoplasmic staining pattern of the CLTC-ALK fusion in T-cell/null ALCL and its similarity to the expression of ALK protein in ALK ϩ DLBCL, suggest a prominent role for this translocation in this unusual subtype of DLBCL.…”

Section: Discussionmentioning

confidence: 99%

ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases

Gascoyne¹

2003

Blood

262

203

View full text Add to dashboard Cite

“…Up to now, 15 cases of ALK þ DLBCL have been reported in literature. [41][42][43][44][45][46][47] These cases are characterized by a distinct morphology and phenotype. The tumor is composed of a diffuse, rather monotonous proliferation of large immunoblast-or plasmablast-like cells with a plasma cell phenotype (CD20À/CD79a7/CD138 þ ) and a strong submembranous granular cytoplasmic staining for ALK.…”

Section: Alk þ Dlbclmentioning

confidence: 99%

Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities

2006

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) as defined by the World Health Organization (WHO) classification is clinically, morphologically and genetically a heterogeneous group of malignant proliferations of large lymphoid B cells. Over the last 6 years, several studies have been published improving our understanding of these lymphomas. These studies analyzed DLBCL by their gene expression profile, provided further information on some of the variants of DLBCL listed in the WHO classification and stressed the impact of the site of origin of these tumors. This review summarizes these recent data and explores their impact on the recognition of new clinicopathological lymphoma entities.

show abstract

ALK+, CD30−, CD20− Large B-Cell Lymphoma Containing Anaplastic Lymphoma Kinase (ALK) Fused to Clathrin Heavy Chain Gene (CLTC)

Abstract: , CD20؊ large B-cell lymphoma, she was treated with conventional combination chemotherapies. However, the lymphoma was primarily chemotherapy resistant, and the patient died 11 months after admission. We consider that this case confirms the existence of ALK

Cited by 76 publications

References 17 publications

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK

ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases

Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities

Contact Info

Product

Resources

About